Synspira is developing a new class of glycopolymer-based therapeutics that target infection and inflammation, the key drivers of pulmonary decline in diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD) and pneumonia. Mucus and biofilm accumulation in these diseases makes the use of antibiotics ineffective, further exacerbating the condition, reducing lung function, and increasing the potential for the development of antibiotic resistance.

Our unique approach seeks to:

  • Disrupt biofilms, thereby rendering otherwise protected bacteria susceptible to antibiotics.
  • Potentiate the activity of current antibiotics by increasing bacterial sensitivity and decreasing resistance.
  • Reduce the viscosity and adhesion of mucus, allowing for pulmonary clearance.
  • Address the complications of pulmonary diseases for which current treatment options are limited.

Learn more about our lead program on Cystic Fibrosis

Synspira has an exclusive worldwide license to Synedgen’s glycomics technology platform for the development of inhaled glycopolymer-based therapeutics in pulmonary indications.